Arcutis CFO Scott Burrows resigns; former CFO John Smither named interim CFO

Arcutis Biotherapeutics, Inc.

Scott Burrows resigns as CFO effective Aug 31, 2023 to pursue external opportunity; no disagreement with company.
John Smither, Arcutis' first CFO (2019-2021), appointed interim CFO effective Aug 31, 2023.
Smither has over 25 years pharma finance experience, including CFO roles at Kythera, Unity, Sienna, and interim CFO at Kite.
Smither will serve as principal financial and accounting officer; compensation terms to be disclosed later.
Company has commenced search for permanent CFO.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott Burrows

chief financial officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2023-08-31
Successor: John Smither
Filed: August 18, 2023, 7:59 PM ET

On August 15, 2023, Scott Burrows notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer of the Company, effective as of August 31, 2023.

Appointed (interim)

John Smither

interim chief financial officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2023-08-31
Filed: August 18, 2023, 7:59 PM ET

The Company has commenced a search for a permanent chief financial officer and has appointed John Smither, who previously served as the Company’s chief financial officer from May 2019 until his retirement in March 2021, as interim chief financial officer, effective upon Mr. Burrows’ departure from the Company on August 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Scott Burrows resigned as chief financial officer at Arcutis Biotherapeutics, Inc..

Action: resigned
Role: chief financial officer

Exact text from the filing

On August 15, 2023, Scott Burrows notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer of the Company, effective as of August 31, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

John Smither was appointed as interim chief financial officer at Arcutis Biotherapeutics, Inc..

Action: appointed
Role: interim chief financial officer

Exact text from the filing

The Company has commenced a search for a permanent chief financial officer and has appointed John Smither, who previously served as the Company’s chief financial officer from May 2019 until his retirement in March 2021, as interim chief financial officer, effective upon Mr. Burrows’ departure from the Company on August 31, 2023.

View on SEC.gov

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-23-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.